852 results on '"Geng, Meiyu"'
Search Results
102. Discovery of novel type II c-Met inhibitors based on BMS-777607
103. A novel long non-coding RNA-ARA: Adriamycin Resistance Associated
104. Molecularly targeted cancer therapy: some lessons from the past decade
105. Discovery of Novel Imidazo[4,5-c]quinoline Derivatives to Treat Inflammatory Bowel Disease (IBD) by Inhibiting Multiple Proinflammatory Signaling Pathways and Restoring Intestinal Homeostasis
106. Development of a novel lactate dehydrogenase A inhibitor with potent antitumor activity and immune activation
107. O-GlcNAcylation of Cofilin Promotes Breast Cancer Cell Invasion
108. Synthesis and biological evaluation of 2-amino-5-aryl-3-benzylthiopyridine scaffold based potent c-Met inhibitors
109. Synthesis and antitumor activities of naturally occurring oleanolic acid triterpenoid saponins and their derivatives
110. Discovery of novel 2-aminopyridine-3-carboxamides as c-Met kinase inhibitors
111. Structure-Based Discovery of a Series of NSD2-PWWP1 Inhibitors
112. Chronic Kidney Disease and Cognitive Impairment: The Kidney-Brain Axis
113. Withaphysalins from Medicinal and Edible Physalis minima and Their Anti-inflammatory Activities
114. HER2/PD1 bispecific antibody in IgG4 subclass with superior anti‐tumour activities
115. Discovery of novel c-Met kinase inhibitors bearing a thieno[2,3- d]pyrimidine or furo[2,3- d]pyrimidine scaffold
116. Synthesis and biological evaluation of cytotoxic activity of novel anthracene l-rhamnopyranosides
117. LS‐106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo
118. Structure-based Discovery of a Series of NSD2-PWWP1 Inhibitors
119. Structure-Based Discovery of Potent CARM1 Inhibitors for Solid Tumor and Cancer Immunology Therapy
120. Design, Synthesis, and Pharmacological Evaluation of Biaryl-Containing PD-1/PD-L1 Interaction Inhibitors Bearing a Unique Difluoromethyleneoxy Linkage
121. Structure-based Discovery of a Series of NSD2-PWWP1 Inhibitor
122. D11, a novel glycosylated diphyllin derivative, exhibits potent anticancer activity by targeting topoisomerase IIα
123. The role of histone deacetylase 7 (HDAC7) in cancer cell proliferation: regulation on c-Myc
124. The glycan profile of endothelial cells in the present of tumor-conditioned medium and potential roles of β-1,6-GlcNAc branching on HUVEC conformation
125. MS80, a novel sulfated polysaccharide, inhibits CD40-NF-κB pathway via targeting RIP2
126. Corrigendum to “Metabolism-based structure optimization: Discovery of a potent and orally available tyrosine kinase ALK inhibitor bearing the tetracyclic benzo[b]carbazolone core” [Bioorg. Med. Chem. Lett. 26 (2016) 5399–5402]
127. Corrigendum to “A novel long non-coding RNA-ARA: Adriamycin resistance-associated” [Biochem. Pharmacol. 87 (2014) 254–283]
128. Corrigendum to “Design, synthesis, and biological evaluation of a new class of histone acetyltransferase p300 inhibitors” [Eur. J. Med. Chem. 180 (2019) 171e190]
129. Identification of AOSC-binding proteins in neurons
130. N-acetylglucosaminyltransferase V Modifies TrKA Protein, Regulates the Receptor Function
131. N-acetylglucosaminyltransferase V mediates cell migration and invasion of mouse mammary tumor cells 4TO7 via RhoA and Rac1 signaling pathway
132. Measures of bioavailable serum sex hormone levels in aging Chinese by protein chip
133. Discovery of Novel Pyrrolo[2,3-d]pyrimidine-based Derivatives as Potent JAK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors
134. Structure–Activity Relationship Study of Amidobenzimidazole Analogues Leading to Potent and Systemically Administrable Stimulator of Interferon Gene (STING) Agonists
135. AL3810, a multi-tyrosine kinase inhibitor, exhibits potent anti-angiogenic and anti-tumour activity via targeting VEGFR, FGFR and PDGFR
136. Oligomannurarate sulfate sensitizes cancer cells to doxorubicin by inhibiting atypical activation of NF-κB via targeting of Mre11
137. Design and Synthesis of a Series of Novel Bisquinazoline Glycosides as Epidermal Growth Factor Receptor Inhibitors
138. The Role of Polymeric Immunoglobulin Receptor in Inflammation-Induced Tumor Metastasis of Human Hepatocellular Carcinoma
139. Causal communication between gut microbiota dysbiosis and neuroinflammation in Alzheimer’s disease and therapeutic intervention by oligomannate
140. A 36-week Multicenter, Randomised, Double-blind, Placebo-controlled, Parallel-group, Phase 3 Clinical Trial of Sodium Oligomannate for Mild-to-Moderate Alzheimer's Dementia
141. Abstract 3737: Mutant isocitrate dehydrogenase driven metabolic reprogramming results in therapeutic vulnerability to lactate dehydrogenase inhibition
142. Abstract 3760: HH2710, a highly potent and selective erk1/2 inhibitor for the treatment of mapk mutant tumors
143. Correction: Undecylprodigiosin Induced Apoptosis in P388 Cancer Cells Is Associated with Its Binding to Ribosome
144. Corrigendum to “SOMCL-863, a novel, selective and orally bioavailable small-molecule c-Met inhibitor, exhibits antitumor activity both in vitro and in vivo” [Cancer Lett. 351 (2014) 143–50]
145. Abstract A83: In vitro and In vivo antitumor activity of immune suppressant FTY720
146. Abstract A78: Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models
147. Abstract B61: Transcriptomic landscape of the immune suppressant FTY720 in antitumor
148. Correction: Down-regulation of G9a triggers DNA damage response and inhibits colorectal cancer cells proliferation
149. Phosphoglycerate Mutase 1 Predicts the Poor Prognosis of Oral Squamous Cell Carcinoma and is Associated with Cell Migration - Erratum
150. T-cell receptor (TCR)/CD3 is involved in sulfated polymannuroguluronate (SPMG)-induced T lymphocyte activation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.